Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma

被引:0
作者
Raue, F. [1 ]
Frank-Raue, K. [1 ]
机构
[1] Humangenet Gemeinschaftspraxis Heidelberg, D-69120 Heidelberg, Germany
关键词
Multiple endocrine neoplasia type 2; Medullary thyroid carcinoma; Pheochromocytoma; Primary hyperparathyroidism; RET proto-oncogene mutation;
D O I
10.1007/s00112-008-1740-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Multiple endocrine neoplasia type 2 is a rare hereditary tumour syndrome characterised by the presence of medullary thyroid carcinoma, primary hyperparathyroidism, and bilateral pheochromocytoma in a single patient. The expression and penetrance of the different tumours is variable depending on the different mutations of the RET proto-oncogene-on one end of the spectrum, an aggressive medullary thyroid carcinoma can exist in a young child, and on the other end, an older individual might have a mild asymptomatic tumour. The specific RET mutation guides the timing of prophylactic thyroidectomy and the extent of surgery. Cure of hereditary medullary thyroid carcinoma is possible. Good cooperation among paediatrician, endocrinologist, geneticist, and surgeon is necessary when caring for families with a child with multiple endocrine neoplasia type 2.
引用
收藏
页码:981 / +
页数:5
相关论文
共 12 条
  • [1] A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
    Berndt, I
    Reuter, M
    Saller, B
    Frank-Raue, K
    Groth, P
    Grussendorf, M
    Raue, F
    Ritter, MM
    Höppner, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) : 770 - 774
  • [2] Guidelines for diagnosis and therapy of MEN type 1 and type 2
    Brandi, ML
    Gagel, RF
    Angeli, A
    Bilezikian, JP
    Beck-Peccoz, P
    Bordi, C
    Conte-Devolx, B
    Falchetti, A
    Gheri, RG
    Libroia, A
    Lips, CJM
    Lombardi, G
    Mannelli, M
    Pacini, F
    Pondder, BAJ
    Raue, F
    Skogseid, B
    Tamburrano, G
    Thakker, RV
    Thompson, NW
    Tomassetti, P
    Tonelli, F
    Wells, SA
    Marx, SJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) : 5658 - 5671
  • [3] The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis
    Eng, C
    Clayton, D
    Schuffenecker, I
    Lenoir, G
    Cote, G
    Gagel, RF
    vanAmstel, HKP
    Lips, CJM
    Nishisho, I
    Takai, SI
    Marsh, DJ
    Robinson, BG
    FrankRaue, K
    Raue, F
    Xue, FY
    Noll, WW
    Romei, C
    Pacini, F
    Fink, M
    Niederle, B
    Zedenius, J
    Nordenskjold, M
    Komminoth, P
    Hendy, GN
    Gharib, H
    Thibodeau, SN
    Lacroix, A
    Frilling, A
    Ponder, BAJ
    Mulligan, LM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19): : 1575 - 1579
  • [4] Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy:: impact of individual RET genotype
    Frank-Raue, K.
    Buhr, H.
    Dralle, H.
    Klar, E.
    Senninger, N.
    Weber, T.
    Rondot, S.
    Hoeppner, W.
    Raue, F.
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2006, 155 (02) : 229 - 236
  • [5] Frank-Raue K, 2003, DEUT MED WOCHENSCHR, V128, P1998
  • [6] Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype
    FrankRaue, K
    Hoppner, W
    Frilling, A
    Kotzerke, J
    Dralle, H
    Haase, R
    Mann, K
    Seif, F
    Kirchner, R
    Rendl, J
    Deckart, HF
    Ritter, MM
    Hampel, R
    Klempa, J
    Scholz, GH
    Raue, F
    Bogner, U
    Brabant, G
    Grussendorf, M
    Hartenstein, CH
    Heidemann, P
    Hensen, J
    Dorr, AG
    Hohne, T
    HornigFranz, I
    Hufner, M
    Kress, I
    Langer, HJ
    Lottermoser, K
    Schweikert, HU
    Kusterer, K
    Menken, U
    Mercier, J
    Oelkers, W
    Ziegler, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) : 1780 - 1783
  • [7] Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin
    Grauer, A
    Raue, F
    Ziegler, R
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 (04) : 353 - 359
  • [8] Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter:: German evidence-based consensus recommendation
    Karges, W
    Dralle, H
    Raue, F
    Mann, K
    Reiners, C
    Grussendorf, M
    Hüfner, M
    Niederle, B
    Brabant, G
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2004, 112 (01) : 52 - 58
  • [9] RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
    Kouvaraki, MA
    Shapiro, SE
    Perrier, ND
    Cote, GJ
    Gagel, RF
    Hoff, AO
    Sherman, SI
    Lee, JE
    Evans, DB
    [J]. THYROID, 2005, 15 (06) : 531 - 544
  • [10] Early malignant progression of hereditary medullary thyroid cancer
    Machens, A
    Niccoli-Sire, P
    Hoegel, J
    Frank-Raue, K
    van Vroonhoven, TJ
    Roeher, HD
    Wahl, RA
    Lamesch, P
    Raue, F
    Conte-Devolx, B
    Dralle, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (16) : 1517 - 1525